URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Marion Mccourt Biography and Net Worth

EVP of Regeneron Pharmaceuticals

Marion McCourt joined Regeneron in 2018 and serves as Executive Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 year at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

What is Marion Mccourt's net worth?: The estimated net worth of Marion Mccourt is at least $9.08 million as of July 1st, 2024. Ms. Mccourt owns 12,931 shares of Regeneron Pharmaceuticals stock worth more than $9,075,622 as of December 21st. This net worth estimate does not reflect any other investments that Ms. Mccourt may own. Learn More about Marion Mccourt's net worth.
How do I contact Marion Mccourt?: The corporate mailing address for Ms. Mccourt and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Marion Mccourt's contact information.
Has Marion Mccourt been buying or selling shares of Regeneron Pharmaceuticals?: Marion Mccourt has not been actively trading shares of Regeneron Pharmaceuticals during the past quarter. Most recently, Marion Mccourt sold 1,137 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a transaction totalling $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares of the company's stock, valued at $13,540,179.41. Learn More on Marion Mccourt's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Marion Mccourt Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/1/2024	Sell	1,137	$1,047.11	$1,190,564.07	12,931
3/1/2024	Sell	358	$967.50	$346,365.00	13,431
2/5/2024	Sell	1,000	$934.71	$934,710.00	13,789
11/1/2023	Sell	1,000	$783.91	$783,910.00	19,803
10/2/2023	Sell	1,038	$827.00	$858,426.00	19,803
7/3/2023	Sell	250	$710.09	$177,522.50	20,303
6/1/2023	Sell	250	$736.00	$184,000.00	20,553
4/3/2023	Sell	1,100	$818.80	$900,680.00	20,803
3/1/2023	Sell	1,100	$759.89	$835,879.00	20,803
2/7/2023	Sell	1,000	$769.04	$769,040.00	22,079
12/12/2022	Sell	264	$730.17	$192,764.88	19,106
11/4/2022	Sell	1,000	$727.82	$727,820.00	19,644
10/3/2022	Sell	1,100	$705.39	$775,929.00	19,644
8/1/2022	Sell	1,100	$581.53	$639,683.00	19,644
7/1/2022	Sell	1,100	$587.76	$646,536.00	19,644
5/2/2022	Sell	1,100	$656.97	$722,667.00	19,644
4/1/2022	Sell	1,000	$701.82	$701,820.00	22,014
2/1/2022	Sell	1,000	$607.46	$607,460.00
12/13/2021	Sell	344	$653.12	$224,673.28
12/1/2021	Sell	1,000	$639.13	$639,130.00
10/1/2021	Sell	1,000	$576.75	$576,750.00
8/2/2021	Sell	1,000	$577.12	$577,120.00	18,038
5/7/2021	Sell	1,000	$495.63	$495,630.00	18,038
10/5/2020	Sell	1,000	$600.00	$600,000.00	14,963

Marion Mccourt Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.